BioPharma Dive 2026-02-12 BridgeBio scores with dwarfism drug, setting up showdown with BioMarin, Ascendis
BioPharma Dive 2026-02-11 Gilead dips as ‘strong’ earnings outweighed by high expectations for new HIV drug
BioPharma Dive 2026-02-10 Nektar, continuing comeback, says eczema drug’s effects hold up in follow-up study
BioPharma Dive 2026-02-09 Lilly buys ‘in vivo’ CAR-T maker Orna, extending streak of genetic medicine deals
BioPharma Dive 2026-02-06 White House’s online service for drug sales debuts with limited impact on prices
BioPharma Dive 2026-02-05 Earnings roundup: AbbVie angst, a bifurcated vaccine market and Bristol Myers’ waiting game